These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36111020)

  • 21. The prognostic impact of K-RAS mutations in adult acute myeloid leukemia patients treated with high-dose cytarabine.
    Ahmad EI; Gawish HH; Al Azizi NM; Elhefni AM
    Onco Targets Ther; 2011; 4():115-21. PubMed ID: 21792317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML.
    Schwarer AP; Butler J; Jackson K; Beligaswatte A; Martin L; Kennedy G; Daniela Z; Lewis I; Hiwase D; Wight J; He S; Grigg A; Morris K; Mollee P; Marlton P
    Hemasphere; 2018 Dec; 2(6):e158. PubMed ID: 31723796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission.
    Miyamoto T; Nagafuji K; Fujisaki T; Uchida N; Matsue K; Henzan H; Ogawa R; Takase K; Aoki T; Hidaka M; Teshima T; Taniguchi S; Akashi K; Harada M;
    Int J Hematol; 2018 Apr; 107(4):468-477. PubMed ID: 29243031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibiotic use during cytarabine consolidation in acute myeloid leukemia.
    Vale CA; Egan PC; Ingham R; Farmakiotis D; Reagan JL
    Ann Hematol; 2021 Jan; 100(1):79-84. PubMed ID: 32870366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outpatient consolidation chemotherapy with intermediate dose cytarabine has similar survival and relapses rates in acute myeloid leukemia as compared to high dose cytarabine: A single center analysis.
    Sljivic I; Fulford A; Ho J; Lazo-Langner A; Xenocostas A; Deotare U
    Eur J Haematol; 2023 Dec; 111(6):888-894. PubMed ID: 37640495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Studies of treatment strategy and prognosis on acute myeloid leukemia with chromosome 8 and 21 translocation].
    Shi HX; Jiang B; Qiu JY; Lu XJ; Fu JF; Wang DB; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Aug; 26(8):481-4. PubMed ID: 16383240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of adult patients with acute myeloid leukemia and unsuccessful cytogenetic analysis undergoing allogeneic hematopoietic stem cell transplantation.
    Vasudevan Nampoothiri R; Chen S; Pasic I; Al-Shaibani Z; Lam W; Michelis FV; Kim DDH; Viswabandya A; Gerbitz A; Lipton JH; Kumar R; Mattsson J; Law AD
    Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):134-140. PubMed ID: 33049225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature.
    Kolla BC; Halim NAA; Cao Q; Sachs Z; Warlick E; Weisdorf D; Ho AYL; Chuan WG; Lao Z; He F
    Br J Haematol; 2021 Jul; 194(1):140-144. PubMed ID: 33843048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose cytarabine chemotherapy (≥4 g/m
    Nagahata Y; Kondo T; Ono Y; Hiramoto N; Kitano T; Hishizawa M; Yamashita K; Hashimoto H; Ishikawa T; Takaori-Kondo A
    Leuk Lymphoma; 2020 Dec; 61(13):3128-3136. PubMed ID: 32804016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
    Kimby E; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Prognostic Impact of K-RAS Mutations in Adult Acute Myeloid Leukemia Patients Treated with High Dose Cytarabine.
    Ahmad EI; Gawish HH; Al-Azizi NM; El-Hefni AM
    J Egypt Natl Canc Inst; 2009 Dec; 21(4):343-50. PubMed ID: 21415871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autologous hematopoietic stem cell transplantation followed by interleukin-2 for adult acute myeloid leukemia patients with favorable or intermediate risk after complete remission.
    Zeng Q; Xiang B; Liu Z
    Ann Hematol; 2022 Aug; 101(8):1711-1718. PubMed ID: 35570208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia.
    Fedele PL; Avery S; Patil S; Spencer A; Haas M; Wei A
    Intern Med J; 2014 Aug; 44(8):757-63. PubMed ID: 24863325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission.
    Chalandon Y; Barnett MJ; Horsman DE; Conneally EA; Nantel SH; Nevill TJ; Nitta J; Shepherd JD; Sutherland HJ; Toze CL; Hogge DE
    Biol Blood Marrow Transplant; 2002; 8(8):435-43. PubMed ID: 12234169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prognosis and chromosomal abnormalities in 79 children with t (8;21) acute myeloid leukemia].
    Chen YM; Liu TF; Ruan M; Zou Y; Chen XJ; Guo Y; Wang SC; Zhu XF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):542-6. PubMed ID: 19968066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical heterogeneity under induction with different dosages of cytarabine in core binding factor acute myeloid leukaemia.
    Wang B; Zhang J; Hua X; Li H; Wang Z; Yang B
    Sci Rep; 2020 Jan; 10(1):685. PubMed ID: 31959790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
    Borlenghi E; Cattaneo C; Cerqui E; Archetti S; Bertoli D; Bellotti D; Gramegna D; Soverini G; Oberti M; Schieppati F; Pagani C; Passi A; Sciumé M; Farina M; Carbone C; Crippa C; Dalceggio D; Tucci A; Rossi G
    Hematol Oncol; 2020 Dec; 38(5):754-762. PubMed ID: 32950042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autologous hematopoietic cell transplantation following high-dose cytarabine consolidation for core-binding factor-acute myeloid leukemia in first complete remission: a phase 2 prospective trial.
    Choi EJ; Lee JH; Kim H; Choi Y; Lee WS; Lee SM; Park JH; Park HS; Lee JH; Lee KH;
    Int J Hematol; 2021 Jun; 113(6):851-860. PubMed ID: 33655416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Analysis of Therapy and Efficacy after Remission of Acute Myeloid Leukemia].
    Zhao SY; Tuerxun N; Chen R; Hao JP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1721-1724. PubMed ID: 28024483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.